Personensuche
Personensuche
Es wurde 1 Person gefunden.
FB Medizin, Universitätsklinikum Essen, Klinik für Hämatologie und Stammzelltransplantation
Anschrift
Hufelandstraße 55
45147 Essen
45147 Essen
Telefon
Telefax
E-Mail
Funktionen
-
, Klinik für Hämatologie
Aktuelle Veranstaltungen
-
SoSe 2025
Vergangene Veranstaltungen (max. 10)
-
WiSe 2024
-
SoSe 2024
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Health-related quality of life in patients with aggressive non-Hodgkin lymphoma : results from the PETAL trialIn: Annals of Hematology , Jg. 104 2025, Nr. 5, S. 2831 – 2845DOI (Open Access)
-
Integrating genetic subtypes with PET scan monitoring to predict outcome in diffuse large B-cell lymphomaIn: Nature Communications , Jg. 16 2025, Nr. 1, 109DOI (Open Access)
-
Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma : an open-label, multicentre phase I/II study (DSHNHL-R6)In: Annals of Hematology , Jg. 104 2025, Nr. 4, S. 2317 – 2325DOI (Open Access)
-
Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21) : a randomised, multicentre, parallel, open-label, phase 3 trialIn: Lancet , Jg. 404 2024, Nr. 10450, S. 341 – 352DOI (Open Access)
-
Omission of Radiotherapy in Primary Mediastinal B-Cell Lymphoma : IELSG37 Trial ResultsIn: Journal of Clinical Oncology (JCO) , Jg. 42 2024, Nr. 34, S. 4071 – 4083
-
Response-guided first-line therapy and treatment of relapse in aggressive lymphoma : 10-year follow-up of the PETAL trialIn: Blood Neoplasia , Jg. 1 2024, Nr. 3, 100018DOI, Online Volltext (Open Access)
-
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma : Final Analysis of the Ro-CHOP TrialIn: Journal of Clinical Oncology (JCO) , Jg. 42 2024, Nr. 14, S. 1612 – 1618DOI (Open Access)
-
Validation of an Artificial Intelligence–Based Prediction Model Using 5 External PET/CT Datasets of Diffuse Large B-Cell LymphomaIn: Journal of Nuclear Medicine (JNM) , Jg. 65 2024, Nr. 11, S. 1802 – 1807
-
An artificial intelligence method using FDG PET to predict treatment outcome in diffuse large B cell lymphoma patientsIn: Scientific Reports , Jg. 13 2023, Nr. 1, 13111DOI (Open Access)
-
Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large B-cell lymphomaIn: Blood , Jg. 141 2023, Nr. 25, S. 3055 – 3064DOI (Open Access)
-
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphomaIn: Blood Advances , Jg. 7 2023, Nr. 2, S. 214 – 223DOI (Open Access)
-
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomasIn: Cancer Cell , Jg. 41 2023, Nr. 1, S. 210 – 225.e5DOI (Open Access)
-
Long-Term Follow-Up of Patients with Conjunctival Lymphoma after Individualized Lens-Sparing Electron Radiotherapy : Results from a Longitudinal StudyIn: Cancers , Jg. 15 2023, Nr. 22, 5433DOI (Open Access)
-
MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy : imaging remission criteria and volumetric regression kineticsIn: Scientific Reports , Jg. 13 2023, Nr. 1, 4792DOI, Online Volltext (Open Access)
-
Neutropenia-related aspergillosis in non-transplant haematological patients hospitalised under ambient air versus purified air conditionsIn: Mycoses , Jg. 66 2023, Nr. 6, S. 505 – 514DOI (Open Access)
-
Outcome prediction by interim positron emission tomography and IgM monoclonal gammopathy in diffuse large B-cell lymphomaIn: Annals of Hematology , Jg. 102 2023, Nr. 12, S. 3445 – 3455DOI (Open Access)
-
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma : A pooled trials analysisIn: Annals of Hematology , Jg. 102 2023, Nr. 10, S. 2791 – 2801DOI (Open Access)
-
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma : Final results of the prospective, multicentre GOAL trialIn: British Journal of Haematology , Jg. 198 2022, Nr. 3, S. 482 – 491DOI (Open Access)
-
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphomaIn: Blood Advances , Jg. 6 2022, Nr. 23, S. 5995 – 6004DOI (Open Access)
-
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma : final results of an open-label, randomized, multicenter phase II trialIn: Leukemia and Lymphoma 2022
-
Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell LymphomaIn: Clinical Lymphoma, Myeloma & Leukemia , Jg. 22 2022, Nr. 6, S. 382 – 392DOI (Open Access)
-
Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/ transformationIn: Haematologica / The Hematology Journal , Jg. 107 2022, Nr. 9, S. 2144 – 2153DOI (Open Access)
-
Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma : First analysis of toxicity and efficacy signalsIn: Leukemia and Lymphoma , Jg. 63 2022, Nr. 1, S. 84 – 92DOI (Open Access)
-
Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma : Results from the PETAL trialIn: Journal of Cancer Research and Clinical Oncology , Jg. 148 2022, Nr. 10, S. 2611 – 2621DOI (Open Access)
-
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphomaIn: Infection - A Journal of Infectious Disease , Jg. 50 2022, Nr. 4, S. 925 – 932DOI (Open Access)
-
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification : A post-hoc analysis of the PETAL trialIn: Leukemia , Jg. 36 2022, Nr. 12, S. 2845 – 2852DOI (Open Access)
-
Long-term follow-up and health-related quality of life among cancer survivors with stage IEA orbital-type lymphoma after external photon-beam radiotherapy : Results from a longitudinal studyIn: Hematological Oncology , Jg. 40 2022, Nr. 5, S. 922 – 929DOI (Open Access)
-
Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple MyelomaIn: Cancers , Jg. 14 2022, Nr. 8, 1955DOI, Online Volltext (Open Access)
-
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma : A German Hodgkin Study Group multicentre real-world analysisIn: British Journal of Haematology , Jg. 198 2022, Nr. 2, S. 401 – 404DOI (Open Access)
-
Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma : International Metabolic Prognostic IndexIn: Journal of Clinical Oncology (JCO) , Jg. 40 2022, Nr. 21, S. 2352 – 2360DOI (Open Access)
-
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma : An experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)In: British Journal of Haematology , Jg. 196 2022, Nr. 3, S. 606 – 616DOI (Open Access)
-
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma : Results of the Ro-CHOP Phase III Study (Conducted by LYSA)In: Journal of Clinical Oncology (JCO) , Jg. 40 2022, Nr. 3, S. 242 – 251
-
The ECHELON-2 Trial : 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphomaIn: Annals of Oncology , Jg. 33 2022, Nr. 3, S. 288 – 298DOI (Open Access)
-
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNAIn: Nature Biotechnology , Jg. 39 2021, Nr. 12, S. 1537 – 1547DOI (Open Access)
-
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma : Results from the prospective, multicenter PETAL and OPTIMAL>60 trialsIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 48 2021, Nr. 11, S. 3550 – 3559DOI (Open Access)
-
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma : Results from the prospective, multicenter PETAL and OPTIMAL>60 trialsIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 48 2021, Nr. 11, S. 3550 – 3559DOI (Open Access)
-
Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations : Comparison of the Deauville 5-Point Scale and the ΔSUVmₐₓ MethodIn: Journal of Nuclear Medicine (JNM) , Jg. 62 2021, Nr. 1, S. 37 – 42DOI (Open Access)
-
Interim PET in Diffuse Large B-Cell LymphomaIn: Journal of Nuclear Medicine (JNM) , Jg. 62 2021, Nr. 8, S. 1068 – 1074DOI (Open Access)
-
Optimal timing and criteria of interim PET in DLBCL : a comparative study of 1692 patientsIn: Blood Advances , Jg. 5 2021, Nr. 9, S. 2375 – 2384DOI (Open Access)
-
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17) : a multicentre, open-label, randomised, phase 3 trialIn: The Lancet Oncology , Jg. 22 2021, Nr. 2, S. 223 – 234
-
Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphomaIn: Blood Cancer Journal , Jg. 11 2021, Nr. 5, 95DOI (Open Access)
-
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomasIn: Blood Advances , Jg. 5 2021, Nr. 13, S. 2707 – 2716DOI (Open Access)
-
Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphomaIn: EJNMMI Research , Jg. 11 2021, Nr. 1, 90DOI (Open Access)
-
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell LymphomaIn: Journal of Clinical Oncology (JCO) , Jg. 39 2021, Nr. 23, S. 2605 – 2616DOI (Open Access)
-
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trialIn: Hematological Oncology 2020DOI (Open Access)
-
Corrigendum to ‘Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial’ [Eur J Canc 124 (January 2020) 25–36] (European Journal of Cancer (2020) 124 (25–36), (S0959804919307555), (10.1016/j.ejca.2019.09.027))In: European Journal of Cancer (EJC) , Jg. 136 2020, S. 207 – 208
-
Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma : Post-hoc analysis from the PETAL trialIn: European Journal of Cancer (EJC) , Jg. 124 2020, S. 25 – 36
-
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma : The Randomized Phase 2 German Hodgkin Study Group NIVAHL TrialIn: JAMA Oncology , Jg. 6 2020, Nr. 6, S. 872 – 880DOI (Open Access)
-
Genetic Variants of the NKG2C/HLA-E Receptor : Ligand Axis Are Determinants of Progression-Free Survival and Therapy Outcome in Aggressive B-Cell LymphomaIn: Cancers , Jg. 12 2020, Nr. 11, S. 3429DOI, Online Volltext (Open Access)
-
Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapyIn: Cancer Medicine , Jg. 99 2020, Nr. 22, S. 8386 – 8396DOI, Online Volltext (Open Access)
-
Metabolic tumor volume, cancer cell fraction, and prognosis–the case of T-cell/histiocyte-rich large B-cell lymphomaIn: Leukemia and Lymphoma , Jg. 61 2020, Nr. 6, S. 1372 – 1379
-
Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determinationIn: Data in Brief , Jg. 28 2020, 104976DOI (Open Access)
-
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trialIn: Lancet , Jg. 393 2019, Nr. 10168, S. 229 – 240DOI (Open Access)
-
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome PredictionIn: Cell , Jg. 178 2019, Nr. 3, S. 699 – 713.e19DOI (Open Access)
-
Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvementIn: European Journal of Haematology , Jg. 102 2019, Nr. 3, S. 241 – 250
-
Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial : correlation with interim PET and outcomeIn: Blood Cancer Journal , Jg. 9 2019, Nr. 9, S. 67DOI (Open Access)
-
Reply to J. Wang et alIn: Journal of Clinical Oncology (JCO) , Jg. 37 2019, Nr. 9, S. 755 – 758
-
Serologic response to meningococcal vaccination in patients with cold agglutinin disease (CAD) in the novel era of complement inhibitionIn: Vaccine , Jg. 37 2019, Nr. 44, S. 6682 – 6687
-
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP : results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trialIn: Annals of Hematology , Jg. 98 2019, Nr. 4, S. 897 – 907
-
Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma : an analysis of the German Hodgkin Study Group (GHSG)In: Leukemia , Jg. 33 2019, Nr. 2, S. 439 – 446
-
Treatment Outcome in Patients with Primary or Secondary Transformed Indolent B-Cell LymphomasIn: Oncology Research and Treatment , Jg. 42 2019, Nr. 11
-
Circulating tumor DNA measurements as early outcome predictors in diffuse large B-Cell lymphomaIn: Journal of Clinical Oncology (JCO) , Jg. 36 2018, Nr. 28, S. 2845 – 2853DOI (Open Access)
-
Eculizumab in cold agglutinin disease (DECADE) : an open-label, prospective, bicentric, nonrandomized phase 2 trial.In: Blood Advances , Jg. 2 2018, Nr. 19, S. 2543 – 2549DOI (Open Access)
-
Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantationIn: Blood , Jg. 131 2018, Nr. 13, S. 1464 – 1475DOI (Open Access)
-
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder : A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 TrialsIn: Transplantation , Jg. 102 2018, Nr. 11, S. 1914 – 1923
-
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) : A Multicenter, Randomized Phase III TrialIn: Journal of Clinical Oncology (JCO) , Jg. 36 2018, Nr. 20, S. 2024 – 2034DOI (Open Access)
-
Reply to H.J.A adams et al and C. GisselbrechtIn: Journal of Clinical Oncology (JCO) , Jg. 36 2018, Nr. 32, S. 3273 – 3274
-
Complex Immune Evasion Strategies in Classical Hodgkin LymphomaIn: Cancer Immunology Research , Jg. 5 2017, Nr. 12, S. 1122 – 1132
-
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18) : final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study GroupIn: Lancet , Jg. 390 2017, Nr. 10114, S. 2790 – 2802
-
Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemiaIn: Journal of Antimicrobial Chemotherapy , Jg. 72 2017, Nr. 8, S. 2359 – 2367DOI (Open Access)
-
Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international, prospective, multicenter Phase II trialIn: Journal of Clinical Oncology (JCO) , Jg. 35 2017, Nr. 5, S. 536 – 543DOI (Open Access)
-
Treatment reduction in patients with advanced-stage Hodgkin Lymphoma and negative interim PET : Final results of the international, randomized phase 3 trial HD 18 by the German Hodkin Study GroupIn: Haematologica / The Hematology Journal , Jg. 102 2017, Nr. Suppl. 2, S. 24 – 25
-
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML) : a multicentre, phase 2, randomised controlled trialIn: The Lancet Oncology , Jg. 16 2015, Nr. 16, S. 1691 – 1699
-
Outcome of aggressive non-Hodgkin lymphoma patients with a negative pretreatment positron emission tomography scanIn: Leukemia and Lymphoma , Jg. 56 2015, Nr. 5, S. 1235 – 1235
-
Positron Emission Tomography guided therapy of aggressive lympomas (PETAL) - the predictive value of quantitative PETIn: Journal of Nuclear Medicine (JNM) , Jg. 56 2015, Nr. Suppl. 3, S. 210
-
Updated results from the soraml trial comparing sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosted acute myeloid leukemiaIn: Haematologica / The Hematology Journal , Jg. 100 2015, Nr. Suppl. 1, S. 318 – 318(Open Access)
-
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy : report of a large prospective multicenter trialIn: Blood , Jg. 124 2014, Nr. 26, S. 3870 – 3879
-
Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial)In: Blood , Jg. 124 2014, Nr. 21, S. 391
-
Progranulin Is a Novel Independent Predictor of Disease Progression and Overall Survival in Chronic Lymphocytic LeukemiaIn: PLoS ONE , Jg. 23 2013, Nr. 8, S. e72107DOI (Open Access)
-
Epigenetic Silencing of the Circadian Clock Gene CRY1 is Associated with an Indolent Clinical Course in Chronic Lymphocytic LeukemiaIn: PLoS ONE , Jg. 7 2012, Nr. 12, S. e34347DOI (Open Access)
-
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationIn: Blood , Jg. 120 2012, Nr. 10, S. 2032 – 2041
-
Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in GermanyIn: Annals of Hematology , Jg. 91 2012, Nr. 2, S. 243 – 248
-
Progranulin plasma concentration is a novel independent prognostic marker in chronic lymphocytic leukemiaIn: Onkologie , Jg. 35 2012, Nr. Suppl. 6, S. 100
-
The GMALL-B-ALL/NHL protocol is an effective salvage treatment in relapsed and refractory aggressive B-cell non-Hodgkins lymphomasIn: Onkologie , Jg. 35 2012, Nr. 6, S. 40
-
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantationIn: Blood , Jg. 118 2011, Nr. 13, S. 3504 – 3511
-
Inhibition of the Terminal Complement System Using Eculizumab for the Treatment of Cold Agglutinin Disease (CAD)
184. Tagung der Rheinisch-Westfälischen Gesellschaft für Innere Medizin e.V.,In: Medizinische Klinik , Jg. 105 2010, Nr. 3, S. 213 – 214 -
Pitfalls of interim positron emission tomography scanning in diffuse large B-cell lymphomaIn: Journal of Clinical Oncology (JCO) , Jg. 28 2010, Nr. 27, S. e488 – e489
-
Prevalence of monoclonal gammopathy of undetermindes significance in a densley populated, highly industrialized area in Germany
15th Congress of the European Hematology Association, Spain, Barcelona, June 10–13, 2010,In: Haematologica, the hematology journal , Jg. 95 2010, Nr. Suppl. 2 , S. 394, 0949 -
Prevalence of monoclonal gammopathy of undetermined significance in a densely populated, highly industrialized area in Germany
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie , Jg. 33 2010, Nr. Suppl. 6 , S. 95, V321 -
Prognostic Significance of Molecular Remission in Follicular LymphomaIn: Journal of Clinical Oncology (JCO) , Jg. 28 2010, Nr. 30, S. e613
-
Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression statusIn: Leukemia , Jg. 20 2006, Nr. 10, S. 1774 – 1782
-
Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemiaIn: Leukemia & Lymphoma , Jg. 47 2006, Nr. 6, S. 1053 – 1061
-
Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemiaIn: Blood , Jg. 101 2003, Nr. 7, S. 2748 – 2755
-
CD38 expression is an important prognostic marker in chronic lymphocytic leukaemiaIn: Leukemia , Jg. 16 2002, Nr. 1, S. 30 – 35
-
PET-Guided Brecadd in Older Patients with Advanced-Stage Classic Hodgkin Lymphoma : Results of the Phase 2 Part of the GHSG HD21 Trial
The 66th ASH Annual Meeting, December 7-10, 2024, San Diego, USA,In: Blood , Jg. 144 2024, Nr. Supplement 1, S. 568 – 568DOI (Open Access) -
Targeted Treatment Additions Ibrutinib + Bortezomib + R-CHOP for Higher-Risk DLBCL : Efficacy, Feasibility and Molecular Signatures for Future Treatment Decisions
The 66th ASH Annual Meeting, December 7-10, 2024, San Diego, USA,In: Blood , Jg. 144 2024, Nr. Supplement 1, S. 6188DOI (Open Access) -
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma : GHSG HD21, a randomized study
2024 ASCO Annual Meeting, May 31 - June 4, 2024, Chicago, Ill., USA and online,In: Journal of Clinical Oncology (JCO) , Jg. 42 2024, Nr. 17, Supplement, LBA7000 -
Combining Baseline and End of Treatment Quantitative PET Parameters to Improve Progression-Free Survival Prediction in DLBCLIn: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 50 2023, Nr. Suppl. 1, Annual Congress of the European Association of Nuclear Medicine September 9–13, 2023 Vienna, Austria, S. S47 – S48
-
Comprehensive Analysis of Treatment Related Morbidity and Progression-Free Survival in the GHSG Phase III HD21 TrialIn: Blood , Jg. 142 2023, Nr. Supplement 1: Annual Meeting Abstracts (65th ASH Annual Meeting and Exposition, 9-12 Dezember 2023, San Diego), S. 3057 – 3057DOI (Open Access)
-
Ibrutinib + bortezomib + R-CHOP for higher-risk DLBCL : Efficacy, feasibility and molecular predictors
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment , Jg. 46 2023, Nr. Supplement 5: DGHO Abstracts, S. 24DOI (Open Access) -
Ibrutinib + bortezomib + R‐CHOP for higher‐risk DLBCL : Feasibility, efficacy and molecular predictorsIn: Hematological Oncology , Jg. 41 2023, Nr. S2, 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023, S. 424 – 425DOI (Open Access)
-
Linsenschonende Elektronenbestrahlung bei konjunktivalen Non-Hodgkin Lymphomen : Monozentrische Langzeitdaten zur Efektivität und NebenwirkungenIn: Strahlentherapie und Onkologie: Journal of Radiation Oncology, Biology, Physics , Jg. 199 2023, Nr. Suppl. 1, S. S106DOI (Open Access)
-
Survival Patterns of Non-Randomized Patients in the IELSG37 Study : Deauville Score 4 Is Not Necessarily Associated with Poor Outcome in Primary Mediastinal Lymphoma
65th Annual Meeting of the American-Society-of-Hematology (ASH); DEC 09-12, 2023; San Diego, USA,In: Blood , Jg. 142 2023, Nr. Supplement 1, S. 1718 – 1721DOI (Open Access) -
Treatment related organ toxicities at one year follow-up in patients with advanced stage classical Hodgkin Lymphoma : results from the randomized phase III HD21 trial by the German Hodgkin Study Group
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment , Jg. 46 2023, Nr. Supplement 5: DGHO Abstracts, S. 111DOI (Open Access) -
Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 TherapyIn: Blood , Jg. 140 2022, Nr. Supplement 1: 64th ASH Annual Meeting and Exposition, 10-13 December 2022, New Orleans, S. 8609 – 8610DOI (Open Access)
-
Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
64th ASH Annual Meeting and Exposition, 10-13 December 2022, New Orleans,In: Blood , Jg. 140 2022, Nr. Supplement 1: 64th ASH Annual Meeting Abstracts, S. 1301 – 1303DOI (Open Access) -
External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL
64th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH): DEC 10-13, 2022; New Orleans, USA,In: Blood , Jg. 140 2022, Nr. Supplement 1, S. 777 – 778DOI (Open Access) -
PET/CT bei indolenten Lymphoma : wann und warum?
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment , Jg. 45 2022, Nr. Supplement 2, S. 147DOI (Open Access) -
The Position of MYC Rearrangements in the Genomic Landscape of Diffuse Large B-Cell Lymphoma
64th ASH Annual Meeting and Exposition, 10-13 December 2022, New Orleans,In: Blood , Jg. 140 2022, Nr. Supplement 1: 64th ASH Annual Meeting Abstracts, S. 9261 – 9263DOI (Open Access) -
Treatment Related Morbidity in Patients with Classical Hodgkin Lymphoma : Results of the Ongoing, Randomized Phase III HD21 Trial By the German Hodgkin Study Group
64th Annual Meeting and Exposition of the American Society of Hematology, December 10 - 13, 2022, New Orleans,In: Blood , Jg. 140 2022, Nr. Supplement 1: 64th Annual Meeting, S. 771 – 773DOI (Open Access) -
Combining PET Radiomic Features with MYC Gene Rearrangement Results in High Prediction of Outcome in Diffuse Large B-Cell Lymphoma
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood , Jg. 138 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 451 – 453DOI (Open Access) -
Echelon-2 (NCT01777152), a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin plus CHP VS CHOP in Previously Untreated Patients with CD30-Positive Peripheral T-Cell Lymphoma : 5-Year Results
48th Congress of the Italian Society of Hematology, 24-27 October 2021, Milan, Italy,In: Haematologica / The Hematology Journal , Jg. 106 2021, Nr. 10, S3: 48th Congress of the Italian Society of Hematology, 24-27 October 2021, S. 3DOI (Open Access) -
Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma : A German Hodgkin Study Group (GHSG) Multi-Center Real-World Analysis
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood , Jg. 138 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 4533 – 4535DOI (Open Access) -
Phased variants improve DLBCL minimal residual disease detection at the end of therapyIn: Journal of Clinical Oncology (JCO) , Jg. 39 2021, Nr. 15_Suppl, S. 7565 – 7565DOI (Open Access)
-
The Addition of Rituximab to Cyclophosphamide, Doxorubicine, Vincristine and Prednisone (CHOP) Prolongs Overall Survival in Previously Untreated Mantle Cell Lymphoma : A Long Term Pooled Trials Analysis
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood , Jg. 138 2021, Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 3551 – 3553DOI (Open Access) -
The ECHELON-2 Trial : 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
Society of Hematologic Oncology 9th Annual Meeting ; September 8–11, 2021, Houston, Texas, USA & Virtual Venue,In: Clinical Lymphoma, Myeloma & Leukemia , Jg. 21 2021, Nr. Suppl. 1, S. S411 -
AFM13 in patients with relapsed or refractory Hodgkin Lymphoma : Final results of an open-label, randomized, multicenter phase II trial
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment , Jg. 43 2020, Nr. Suppl. 4, S. 89DOI (Open Access) -
Characteristics of the relationship between MTV and survival in diffuse large B-cell lymphoma : A PETRA consortium study
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging , Jg. 47 2020, Nr. Supplement 1, S. S357DOI (Open Access) -
Classical Hodgkin-Lymphoma : PET-guided therapy and implementation of new substances from a global perspective
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment , Jg. 43 2020, Nr. Suppl. 4, S. 4DOI (Open Access) -
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma : results from the prospective, multicenter PETAL and OPTIMAL > 60 trials
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment , Jg. 43 2020, Nr. Suppl. 4, S. 55 – 56DOI (Open Access) -
Think twice : Anemia of chronic disease (ACD) due to angiomatoid fibrous histiocytoma (AFH)
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment , Jg. 43 2020, Nr. Suppl. 4, S. 181DOI (Open Access) -
Interim results of a multicenter, single-arm study to assess Blinatumomab in adult patients (pts) with minimal residual disease (MRD) of B-precursor (BCP) acute lymphoblastic leukemia (GMALL-MOLACT1-BLINA)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment , Jg. 42 2019, Nr. Supplement 4: Abstracts, S. 174 – 175DOI (Open Access) -
Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)
61st ASH (American Society of Hematology) Annual Meeting & Exposition; Dec 07 - 10 2019; Orlando, USA,In: Blood , Jg. 134 2019, Nr. Supplement_1: 61st ASH Annual Meeting, S. 236 – 236DOI (Open Access) -
Role of FDG PET/CT to Detect Bone Marrow Involvement in the Initial Staging of Aggressive Non-Hodgkin Lymphoma
Konferenz 61st ASH (American Society of Hematology) Annual Meeting & Exposition; Dec 07 - 10 2019; Orlando, USA,In: Blood , Jg. 134 2019, Nr. Supplement_1, S. 2892 – 2892DOI (Open Access) -
Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma
61st ASH Annual Meeting and Exposition, 07.-10.12.2019, Orlando, FL,In: Blood , Jg. 134 2019, Nr. Supplement_1, S. 491 – 491DOI (Open Access) -
The ECHELON-2 trial : Results of a randomised, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) vs CHOP in the frontline treatment of patients (pts) with CD30⁺ peripheral T-cell lymphomas (PTCLs)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment , Jg. 42 2019, Nr. Supplement 4: Abstracts, S. 23DOI (Open Access) -
The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma : An Individual Patient Data Meta-Analysis By the Petra Consortium
61st ASH Annual Meeting and Exposition, 07.-10.12.2019, Orlando, FL,In: Blood , Jg. 134 2019, Nr. Supplement_1, S. 487DOI (Open Access) -
Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma : A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood , Jg. 132 2018, Nr. Supplement 1, S. 2912 – 2912DOI (Open Access) -
Interim PET-Based Outcome Prediction in Diffuse Large B-Cell Lymphoma Patients Participating in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) Trial : Comparison of the Delta SUV Max Method and the Deauville 5-Point Scale
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood , Jg. 132 2018, Nr. Supplement 1, S. 1696 – 1696DOI (Open Access) -
Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing
Konferenz 60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood , Jg. 132 2018, Nr. Supplement 1, S. 2861 – 2861DOI (Open Access) -
Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL TrialIn: Blood , Jg. 132 2018, Nr. Supplement 1: 60th ASH Annual Meeting Abstracts, S. 4188 – 4188DOI (Open Access)
-
Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood , Jg. 132 2018, Nr. Supplement 1, S. 2838 – 2838DOI (Open Access) -
Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma : Â a Phase II Trial (GOAL)
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood , Jg. 132 2018, Nr. Supplement 1, S. 1678 – 1678DOI (Open Access) -
Predominantly motor polyneuropathy following brentuximab vedotin
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment , Jg. 41 2018, Nr. Suppl. 4, S. 319DOI (Open Access) -
The ECHELON-2 Trial : Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood , Jg. 132 2018, Nr. Supplement 1: 60th ASH Annual Meeting Abstracts, S. 997 – 997DOI (Open Access) -
The addition of sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival : Updated results from long-term follow-up of the randomized-controlled SORAML trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment , Jg. 41 2018, Nr. Suppl. 4, S. 9DOI (Open Access) -
Positron-emission tomography-guided therapy of aggressive non-Hodgkin lymphomas -final results of the PETAL trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 29. September-3. Oktober 2017, Stuttgart, Germany,In: Oncology Research and Treatment , Jg. 40 2017, Nr. Suppl. 3, S. 202 – 203 -
DECADE Trial : Inhibition of theterminal complement system using the anti-C5 antibody eculizumab for the treatment of cold agglutinin disease (CAD)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie , Jg. 33 2010, Nr. Suppl. 6, S. 112 -
Prevalence of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Light-Chain MGUS (LCMGUS) In a Metropolitan Area In GermanyIn: Blood , Jg. 116 2010, Nr. 21, 4037
-
Global Phase 2 Basket Trial of Nanatinostat in Combination with Valganciclovir in Patients with EBV-Positive (EBV plus ) Relapsed/Refractory Lymphomas (NAVAL-1, trial in progress)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment , Jg. 46 2023, Nr. Supplement 5: DGHO Abstracts, S. 186 – 187DOI (Open Access) -
Improved Risk Prediction in DLBCL By Combining Clinical and PET Features with Interim PET Assessment
65th ASH Annual Meeting, December 9-12, 2023, San Diego, CA, USA,In: Blood , Jg. 142 2023, Nr. Supplement 1, S. 1740 – 1741DOI (Open Access)